IBDEI0Z5 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16516,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16516,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,16516,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,16517,0)
 ;;=C78.7^^67^759^36
 ;;^UTILITY(U,$J,358.3,16517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16517,1,3,0)
 ;;=3^Secondary Malig Neop Liver & Intrahepatic Bile Duct
 ;;^UTILITY(U,$J,358.3,16517,1,4,0)
 ;;=4^C78.7
 ;;^UTILITY(U,$J,358.3,16517,2)
 ;;=^5001339
 ;;^UTILITY(U,$J,358.3,16518,0)
 ;;=C91.10^^67^759^4
 ;;^UTILITY(U,$J,358.3,16518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16518,1,3,0)
 ;;=3^Lymphocytic Leukemia B-Cell Type,Chronic,Not in Remission
 ;;^UTILITY(U,$J,358.3,16518,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,16518,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,16519,0)
 ;;=D46.9^^67^759^26
 ;;^UTILITY(U,$J,358.3,16519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16519,1,3,0)
 ;;=3^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,16519,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,16519,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,16520,0)
 ;;=C79.31^^67^759^33
 ;;^UTILITY(U,$J,358.3,16520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16520,1,3,0)
 ;;=3^Secondary Malig Neop Brain
 ;;^UTILITY(U,$J,358.3,16520,1,4,0)
 ;;=4^C79.31
 ;;^UTILITY(U,$J,358.3,16520,2)
 ;;=^5001347
 ;;^UTILITY(U,$J,358.3,16521,0)
 ;;=C79.32^^67^759^34
 ;;^UTILITY(U,$J,358.3,16521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16521,1,3,0)
 ;;=3^Secondary Malig Neop Cerebral Meninges
 ;;^UTILITY(U,$J,358.3,16521,1,4,0)
 ;;=4^C79.32
 ;;^UTILITY(U,$J,358.3,16521,2)
 ;;=^5001348
 ;;^UTILITY(U,$J,358.3,16522,0)
 ;;=G89.3^^67^759^28
 ;;^UTILITY(U,$J,358.3,16522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16522,1,3,0)
 ;;=3^Neoplasm Related Pain
 ;;^UTILITY(U,$J,358.3,16522,1,4,0)
 ;;=4^G89.3
 ;;^UTILITY(U,$J,358.3,16522,2)
 ;;=^5004159
 ;;^UTILITY(U,$J,358.3,16523,0)
 ;;=C79.82^^67^759^35
 ;;^UTILITY(U,$J,358.3,16523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16523,1,3,0)
 ;;=3^Secondary Malig Neop Genital Organs
 ;;^UTILITY(U,$J,358.3,16523,1,4,0)
 ;;=4^C79.82
 ;;^UTILITY(U,$J,358.3,16523,2)
 ;;=^267339
 ;;^UTILITY(U,$J,358.3,16524,0)
 ;;=I50.9^^67^760^7
 ;;^UTILITY(U,$J,358.3,16524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16524,1,3,0)
 ;;=3^Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,16524,1,4,0)
 ;;=4^I50.9
 ;;^UTILITY(U,$J,358.3,16524,2)
 ;;=^5007251
 ;;^UTILITY(U,$J,358.3,16525,0)
 ;;=I73.9^^67^760^13
 ;;^UTILITY(U,$J,358.3,16525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16525,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16525,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,16525,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,16526,0)
 ;;=I35.0^^67^760^11
 ;;^UTILITY(U,$J,358.3,16526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16526,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Stenosis
 ;;^UTILITY(U,$J,358.3,16526,1,4,0)
 ;;=4^I35.0
 ;;^UTILITY(U,$J,358.3,16526,2)
 ;;=^5007174
 ;;^UTILITY(U,$J,358.3,16527,0)
 ;;=I35.1^^67^760^10
 ;;^UTILITY(U,$J,358.3,16527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16527,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Insufficiency
 ;;^UTILITY(U,$J,358.3,16527,1,4,0)
 ;;=4^I35.1
 ;;^UTILITY(U,$J,358.3,16527,2)
 ;;=^5007175
 ;;^UTILITY(U,$J,358.3,16528,0)
 ;;=I35.2^^67^760^12
 ;;^UTILITY(U,$J,358.3,16528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16528,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Stenosis w/ Insufficiency
 ;;^UTILITY(U,$J,358.3,16528,1,4,0)
 ;;=4^I35.2
 ;;^UTILITY(U,$J,358.3,16528,2)
 ;;=^5007176
 ;;^UTILITY(U,$J,358.3,16529,0)
 ;;=I35.9^^67^760^9
